In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
Commentary|Podcasts|February 13, 2026
Pharma Pulse: Big Medicine Breakups and the Tariff Scramble
Author(s)Nicholas Saraceno, Senior Editor
In today’s Pharma Pulse, bipartisan lawmakers target PBM vertical integration, while pharma giants race to secure tariff-exempt pricing deals.
Advertisement
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.
- We begin on Capitol Hill. Senators Elizabeth Warren and Josh Hawley have introduced the
Break Up Big Medicine Act . Drawing inspiration from the 1933 Glass-Steagall Act, the bill aims to shatter vertical integration by banning parent companies from simultaneously owning insurers, PBMs, and medical providers. With just three PBMs currently managing 80% of US drug claims, the legislation mandates a one-year divestiture period—or face automatic penalties, including profit disgorgement and forced asset sales. - Meanwhile, pharmaceutical companies left out of the initial Trump pricing deals are now scrambling to secure their own agreements. Facing the threat of massive levies and new Medicare price-setting pilots, manufacturers are
pursuing paths to join the ecosystem. The goal? Aligning with most-favored nation pricing benchmarks in exchange for the same tariff reprieve granted to their competitors.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on
Advertisement
Related to this article
PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
Inside the October 2026 issue: why splitting MMR takes years, why payers cite a price that does not bind them, and what pricing rules broke.
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Why Securing Pharma Freight Starts With Broker and Carrier SOPs
2
LogiPharma USA 2026: Where Cold Chain Expertise Gaps Become Product Risk
3
Supply Chain Visibility Needs Context Before AI, Says PAXAFE’s Mark Talens
4
Pharma Pulse: PhRMA Sues to Block GLOBE Model and Bayer's $2.2B Ohio Site
5